PT - JOURNAL ARTICLE AU - Zhou, Lijun AU - Li, Cheng AU - Yang, Huiping AU - Yuan, Heng AU - Pan, Ming AU - Cheng, Xiuwei AU - Xiao, Chongkun AU - Su, Xiaoyan AU - Zhu, Yuanfang AU - Xu, Jianan AU - Tang, Jianxiang AU - Du, Xunbo AU - Peng, Huanwen AU - Xiao, Chen AU - Huang, Tao AU - Liao, Hongxiu AU - Xian, Deqiang AU - Liao, Hongxiu AU - Wang, HaoZhou AU - Liu, Wenwu AU - Ping, Zhou AU - Zhang, Zhengdong AU - Juan, Liu AU - Wu, Xianping AU - Zhang, Tao TI - SARS-CoV-2 Seroprevalence and Risk Factors among Convalescents in Sichuan Province, China: a retrospective cohort study AID - 10.1101/2021.05.04.21256355 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.04.21256355 4099 - http://medrxiv.org/content/early/2021/05/05/2021.05.04.21256355.short 4100 - http://medrxiv.org/content/early/2021/05/05/2021.05.04.21256355.full AB - Objectives To understand SARS-CoV-2 seroprevalence of convalescents and assess their the immunity. Furthermore, we intend to explore the association between antibody levels and with demographic factors.Methods 177 COVID-19 convalescents in Sichuan Province were voluntarily participated in our study. 363 serum samples were collected from June, 2020 to November, 2020. Duration of seroprevelance in these convalescents and their demographic characteristics were described, and the risk factors to antibody levels were analysed.Results Men had more than twice the odds of having IgM antibody positive compared with women (OR=2.419, 95% CI:[1.232, 4.751]). Participants without symptoms were nearly 0.5 times IgG seropositive than those with symptoms (OR=0.455, 95% CI: [0.220, 0.940]). People agedā‰„60 years were nearly 3 times IgG seropositive than those who aged < 20 years (OR=2.986, 95% CI: [1.058, 8.432]). Seroprevalence in asymptomatic declined quicker than symptomatic.Conclusions Age and gender may affect the antibody levels and seroprevalence. Asymptomatic appeared more easier to turn to seronegative than symptomatic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China (grant numbers 82041033, 81602935), Sichuan Science and Technology Program (grant numbers 2020YFS0015, 2020YFS0091, 2021YFS0001), Health Commission of Sichuan Province (grant number 20PJ092, 20ZDCX001), Chongqing Science and Technology Program (grant number cstc2020jscxcylhX0003), and Humanities and Social Sciences Program of Sichuan University (grant number 2018hhf-26). The funding body did not participate in the design, collection, analysis, interpretation and writing of this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The survey was discussed with the Ethics Committee of Center for Disease Control and Prevention in Sichuan Province, who reviewed the content. And the ethical approval was given. All participants assented informed consent before participation, and this study was conducted in accordance with Good Clinical Practice(GCP). This study was performed in compliance with all relevant ethical regulations and the protocol for human subject studies was approved by the Center for Disease Control and Prevention in Sichuan Province(SCCDCIRB-2020-007).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw/processed data required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study.